Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
Myriad Genetics announced new MONSTAR-SCREEN-3 data showing its WGS-based Precise MRD platform detected residual disease with ultra-sensitivity in resectable colorectal and pancreatic cancers. In colorectal cancer, post-surgical ctDNA was detected ahead of all observed recurrences with a median four-month lead time; more than half of positives were found below 100 parts per million. In pancreatic cancer, a historically low-shedding tumor type, personalized panels were built for all evaluable patients and MRD detection at one month correlated with worse recurrence-free survival.
Key figures
- Drug Name
- Precise MRD
- Phase Of Trial
- MONSTAR-SCREEN-3 (ongoing study)
- Max panel variants
- 1000
- Median lead time months
- 4
- Ctdna detection threshold ppm
- 100
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.